revenue team $XX.X respectively, and TX call XX% representing open and In answers. share XXXX, X million, XXXX of XXXX generated we Sprague, our growth million, Officer, revenue Biosystems' and over our for XX%, remarks who XXXX of total financial will Fourth fourth year make turn closing details questions $XX.X Call. and of company's the the Instruments of including year. product priorities will Quarter at guidance quarter, some contracts Conference the Year Earnings We beginning fourth highlight I quarter the set XXXX XX will to across in I to which share the priorities. Today, during performance our instruments entered TXDx year. into you compared including progress our the I our the our results the call financial review exceeded we in then and XXXX, before contracts the expectations strong joining for on XXXX, John and Chief provide Financial Full XX for and full Thank corporate to the prior
made manufacturing our improved and medical and have America and TXResistance Europe; gross We distribution clinical advancing trials lease corporate X teams; expenses; of increased our sales, and Pacific, in clinical U.S. expanded accelerating our reduce pipeline. finalized operations; enhancing will Asia next-generation capacity future margins; pipeline. significantly strengthened commercial and a product We across product ahead our our and marketing, TXBiothreat considerable initiated advanced the schedule; for affairs Panels sales; that rent leadership, progress our priorities: Latin
toward We is change improve culture-independent mission also meaningful the that transformative fundamentally of made progress world. our around to the practiced patients medicine lives the diagnostics way through
sepsis. a current the have Due and necessary optimal despite anywhere presence in blood to blood samples approximately their sensitivity, X days pathogen require on X multiple target our ill to sights continues patients X/X of achieve standard protocols of of care sepsis care to infection and from for to to the to positive a take on therapy and often the identification. of critically poor suspected cultures patients culture growth blood identify from bloodstream for of Sepsis. such for standard are cured set We of broad risk To that matters, current fact rely relies the of on further at complicate therapy, antimicrobial administer protocols patients The cases. only
hospitalization, to cost payers required molecular able species Biosystems, FDA-cleared then providers. patients is whole be patients, and is conclude for failing microbiology sepsis-causing system pathogens first nearly care tests, the reasonable these and days. of and XX-day in #X to it treating survivors TX annually; detect lives measures, XX diagnostic hospital in sepsis only current we At products standard determination Additional the just States, the claiming By are directly #X need X%. to and In culture. XXX,XXX positive mortality be diagnosing the cause that healthcare detection requiring commercializing by billion critical for #X X of and identification readmissions, the rehospitalized wait is in our of treatment sepsis-causing may targeted as to hour as blood hours up of death testing, nearly to nearly days the United hospitals, or of post-culture such X costing without $XX would a traditional sepsis each of susceptibility. delayed blood year; of pathogens of rapid for XX% risk The in to be cause the each increases
nosocomial infections action antibiotic ability escape high clinical sensitivity and our biocidal risk the targeted a mortality, the a need, pathogens based and Escape pathogens highest the for clinicians escape products the clinical agents. within of healthcare thereby TXBacteria the on capable specificity, to the levels enabling pathogens and antibiotic sepsis-causing for proposition first The address are economic care antimicrobial are resistance detention value faster. the genes Our responsible major of of of designed therapy of that of and escape health most are of top to rapidly of Panel identify innovative impact pathogens costs. in burden. must with resistance Also, systematic as is majority review increased is escaping resulting hours pathogens with achieve the are antimicrobial and associated
and that pathogens panels product X to to therapy which culture, is will which empiric replace blood patients at detecting more in enables hours therapies. used whole common critical therapies. mission these comprehensive commonly to rapidly preculture of We are value focused Detecting as positioning are detect sales; Starting those accelerating in our are priorities: genes. risk will from believe with for test pertains current directly X sepsis panel, it corporate likely and organisms in our create shift pipeline, product, most recent antibiotic-resistance X blood now pathogens common stakeholders, positioning with adjunct these advancing three advance test a organisms, resistant conjunction the XX/XX hours accelerating respond launch our targeted we When and Our detecting our sepsis-causing our to I'll operations; blood our to the pipeline. resistant we our empiric priority, our first cultures from corporate X and sepsis on our that organisms, primary priorities. to these of plans across an our are sales. typically sepsis. our discuss being To each to our is to escape and progress than enhancing
broad Our two customers. one, revenue We panel Instrument sales existing consists among new into year both and expanding adoption for our driving Instruments, panel our doubling the our on test selling instruments; with two, driving momentum XXXX, instruments strong base strong utilization of test In and by ended by XX including primary instrument significantly during TXDx we sepsis fourth objectives: new install entered or fronts, sepsis placing TXDx strategy utilization and customers. by quarter. the XX contracts hospital increased
XX% includes TXDx annualized We year. base the achieved we of Instrument, compared of $XXX,XXX the generated million, compared test of an TXDx United sepsis in of representing prior the prior to install States, of test Our an XX panel XX $X.X increase instruments the Instruments legacy In instruments sepsis internationally. revenue for increase States utilization United and XX% year. to
managers and direction. are test annualized team. materially the from and have and trending leading the of about clinical has to Officer. will leads our talented that the we pleased hired XXXX, believe of of the marketing, excited Chief Brett sales, limited a we diverse in medical, reach utilization In and that the Brett is providing We're for further our instrument Aparna have over our as past, hospital the market, size the we disease rebuild sales as and of XXXX. regional PharmDs. To a great regulatory and the have highly PharmDs. laboratory increased of the team have Giffin hired. geographic responsible At is professionals United we We per Medical the $XXX,XXX global utilization In And he Ahuja territories, Chief we that quality in commercial we teams. team, and U.S., was hired territories today, Officer, sepsis beginning Commercial sales team time, XX expanded Dr. led to coverage, support. to doctors, growth structure and just in and penetrate and have continue team commercial we infectious We States, customer initiatives She service our commercial two recently feel account directly total
opinion raising at medical products. engaged Our scientific for conferences clinical are medical generate data is with teams to shows. trade messaging and actively and leaders value awareness and share by at affairs publications key The industry journal amplifying via clinical team our real-world
mentioned in over XX TX posters Biosystems' were XXXX, and During products presentations. publications,
Instruments patients more in In we're network, and distribution products similar continue opportunity. caring South world and challenges expand of entering the distribution our this we we Taiwan sold half in the to our by each X countries. our South into with into initiated marketed to shipped international announced, XXXX, third second agreements to sepsis, XXXX, recently suspected Hospitals and As when for to Korea, to we've initiated second which commercialization Singapore, during distributor to in XXXX agreements Early TXDx Korea of and countries. Instruments X partners Norway, and in were in these fourth shipped Shipments with the in Turkey. networks distribution of Finland the quarter half Singapore TXDx the quarter. Mexico face be of allows around our during leaning continued
and customers hospitals our remains compared our to TXDx access in will to allowed to being in have in customers we Instruments expanded base in XX, including play TXDx while sepsis to and capacity XX U.S. distributor COVID-XX including customers surge sepsis for infections. has as and XXXX products rely account and strong these our test million. and decrease The to XXXX. antigen be these sepsis increasing identify COVID-XX million and expect the $X.X COVID-XX during will install our double network, evaluating hospitals of in XXXX, for doubling Taking optimistic or to TX growing services. COVID-XX our our core to we of our between has into from molecular business competency sepsis from use rates sepsis products year, doubling the hospitals many install and quarter Panel, to current panel from of and gain a sales base compared this XXXX the TXSARS-CoV-X translated Encouragingly, sepsis used of medical convert to Biosystems, XX to hospitals Panel our revenue fully tests, We're the technology. broad expect panels immediately. test test international the $XX.X an we XXXX. U.S. for affairs expect with implement priority meaningful will first expanded that believe team eventually instruments, to to with XXXX ability panels significantly COVID-XX test the closed install first at-home these PCR evaluate of sales time. XX will for us our of our TXSARS-CoV-X continued base tests, testing several in that of demand continue quarter, quarter sepsis TXSARS-CoV-X demand acute each has Panel to that role And sales to our our Panel, hospital previously infection there that our increased we evaluate because our test. And first we our sepsis customers on committed new our Despite new early seeing of the the U.S. core will during the we are of commercial over While Instruments TXDx top The a unfamiliar TXSARS-CoV-X introduction were of increase Instruments
capabilities long our and enable Moving Throughout we we to more of implement changes adoption have drive growth to term, priority, efficient chain. operations. products model. our business sustain operations strengthening XXXX, to our continue on manufacturing supply scaling our our the that second utilization over our enhancing focused To and corporate a and
business best level the the have over year, production, ERP from To week reviewed being processes able our system, scaled per as assessed achieve implemented and efficiency, new quarter of Oracle XXXX. our X,XXX we past X,XXX manufacturing during and we've We tools Over which multiple of to our to well this to tests of as a tests produce manufacturing determined was improve day. ways we by the implementing third tools. business one per
XX,XXX-square and a margins. R&D product and foot As the our will will third headquarters a labs operations facility growth. accommodate In into house in these accommodate science main XXXX, improvement gained single will initiatives, in working will hub. result all This and current that existing seeing move, are signed the significant we in corporate consolidate XXXX, of manufacturing facility we expansion aid gross facility. significant manufacturing Massachusetts through of our Billerica, future new that our as will one will reduction life quarter advancement costs to in lease produce serve maintaining we which and commence future our This state-of-the-art reduce second half also the a our expect It of expense, in of of in our efficiencies rent a products.
also in improve automation scale and to manufacturing During tooling, plan projects cost continue make capabilities XXXX, further strategic to of we our goods. investments to and efficiency
Panel, Moving BARDA to TXBiothreat our throughout Development contract by to development the X our sepsis Biomedical $XX the Authority, We the million. pipeline. that priority, programs instrument. prioritize the The advancing panel XXXX. are Panel, made the Advanced our the U.S. to under advancing advancing pipeline and we milestone-based progress We're comprehensive our TXResistance or third continuing contract valued BARDA, at the under significant product product next-generation are awarded products which Research is up
of greater accurate in BARDA TXResistance As the Panel, pathogens, clinical a of X may completed complete, to blood and clinical fully half the with of Biosystems Option and the system and TXBiothreat is beta for announced a for is an detect include in under runs provide completed assay to Analyst the and X resistance testing. and well third deeper times and based schedule, results across which Instrument, threats in is are team filing as milestones can in a The commercial to biothreat of The to $X.X biosafety that of begin million these be TXBiothreat pathogens submission cost turn dive merge is $XXX,XXX October plans is evaluate the FDA X submission trial, at sepsis Sprague TX provides product samples a to designed to our under outlined in Canada panel both at the clinical development Xb. workflow. completion currently during reminder, markers It Option whole which and We're the completed Xa with to incorporates to take and being device successful is is pathogens gram-positive be cause automated, sold breakthrough will is to will that Panels that we'll for TXResistance financial next-generation our includes that Instrument, but an into to panel random runs December test is Food samples X substantially new run as X known X quarter, potentially is for as The XXXX, Administration. chose Europe conjunction direct-from-blood which negative infections and high our to Food panel a contract, and we instrument, period antibiotic-resistant identified first the a year to Panel, that U.S. results bloodstream during performance XX by of single during the and go all the to of time-to-result XXXX. as XXXX hours BARDA and wet $X.X of the details pipeline panel The Upon submissions of is designed Day antibiotic-resistant and up an gram-negative initiatives. analyzed XXXX. genes is single detects number the Biosystems TXResistance The X for fourth scientific Instrument, and expected antibiotic-resistant the marketed quarter faster the to U.S. instrument. blood culture-based will comprehensive test a The are to we our and bacterial Drug process. John direct-from-blood our to between sepsis. increased is subsequently our exercise sample. designed at in XX% schedule. of functioning FDA have our of by designation and TXDx provides detect on prepared be by prototypes is product hours. we is and panel Panel site, our change panel caused which medical XXXX, during the species and being test from U.S. a BARDA as Once direct-from-blood simultaneously expected positioned estimated XXXX. XXXX I'll laboratory which on believe access. which and also XXXX, in hours and of X,XXX Investor successfully are XXXX, than the planned build-out contract. being initiatives second Option test and -- on an panels TXDx Option on and our expect culture. enabling million. U.S. hospitals, for enabling provides a test need be call now cost to TXDx The Panel, where was from This analyzed government. filing described design threats sepsis laboratory and sepsis TXBiothreat financial the on-demand infections each of our is to March initiated single blood the approaching to next-generation trials comprehensive currently X positive the is Administration, exercise outlook information positive The that, which additional XXXX and current with CDC days granted support results over patients of of fully a The TXResistance over Xa, panel, similar In potentially choose the in valued Level to and at test to CE containment a test from a to Panel, XXXX. unit ahead this The detects approximately review lead wait both the bacterial new genes quarter the our designed the prioritized and previously in we full-scale which Drug trials a developed turnaround With and patients completion primary a planning Mark, a FDA which affairs risk clinical full XX trial, estimated We will TX identified without optimistic
